Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Intense Temozolomide in Recurrent Glioblastoma
NCT02330991Phase 2Completed
- Sponsor
- Beijing Sanbo Brain Hospital
- Start
- Jan 2015
- Primary completion
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by Beijing Sanbo Brain Hospital. Primary endpoint: Progression-Free Survival at 6 months. Started Jan 2015; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02330991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02330991.